Heriditary Spastic Paraplegia Spg50 clinical trials

Explore recruiting heriditary spastic paraplegia spg50 clinical trials.

Also recruiting in Europe

Heriditary Spastic Paraplegia Spg50 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Heriditary Spastic Paraplegia Spg50 trials by city

Heriditary Spastic Paraplegia Spg50 in Toronto Heriditary Spastic Paraplegia Spg50 in Vancouver Heriditary Spastic Paraplegia Spg50 in Montreal Heriditary Spastic Paraplegia Spg50 in Calgary Heriditary Spastic Paraplegia Spg50 in Edmonton Heriditary Spastic Paraplegia Spg50 in Ottawa Heriditary Spastic Paraplegia Spg50 in Winnipeg Heriditary Spastic Paraplegia Spg50 in Quebec City Heriditary Spastic Paraplegia Spg50 in Hamilton Heriditary Spastic Paraplegia Spg50 in Kitchener Heriditary Spastic Paraplegia Spg50 in London Heriditary Spastic Paraplegia Spg50 in Halifax Heriditary Spastic Paraplegia Spg50 in New York Heriditary Spastic Paraplegia Spg50 in Los Angeles Heriditary Spastic Paraplegia Spg50 in Chicago Heriditary Spastic Paraplegia Spg50 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease